Associations between blood biomarkers, cardiac function and adverse outcome in a young tetralogy of Fallot cohort
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved..
BACKGROUND: To determine the potential prognostic value and clinical correlations of blood biomarkers in a cohort of patients with Tetralogy of Fallot (TOF).
METHODS: In the setting of multicenter prospective research studies TOF patients underwent blood sampling, cardiopulmonary exercise testing and low-dose dobutamine stress cardiac magnetic resonance (CMR) imaging. In the blood sample NT-proBNP, GDF-15, Galectin-3, ST-2, DLK-1, FABP4, IGFBP-1, IGFBP-7, MMP-2, and vWF were assessed. During subsequent follow-up, patients were evaluated for reaching the study endpoint (cardiac death, arrhythmia-related hospitalization or cardioversion/ablation, VO2 max ≤65% of predicted). Regression analysis was used to explore the correlation between blood biomarkers (corrected for age and gender) and other clinical parameters. The potential predictive value of blood biomarkers and events were assessed with Kaplan-Meier analysis and Cox proportional hazard analysis.
RESULTS: We included 137 Fallot patients, median age 19.2 (interquartile range: 14.6-25.7) years, median age at TOF-repair 0.9 (0.5-1.9) years. After a median follow-up of 8.7 (6.3-10.7) years, 20 (14.6%) patients reached the composite endpoint. In a multivariable cox-regression analysis corrected for age at study baseline, elevated IGFBP-7 and MMP-2 levels were associated with the composite endpoint. We also noted a correlation between DLK-1 and relative change in right ventricular end systolic volume during dobutamine stress CMR (β = -0.27, p = 0.010), a correlation between FABP4 and Max VO2 (β = -0.41, p ≤0.001 and between MMP-2 and tricuspid valve E/A ratio (β = -0.15, p = 0.037).
CONCLUSIONS: IGFBP-7, MMP-2 and DLK-1 levels are related to cardiac function and long-term outcome in TOF patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:361 |
|---|---|
| Enthalten in: |
International journal of cardiology - 361(2022) vom: 15. Aug., Seite 31-37 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van den Bosch, Eva [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3S12J47372 |
|---|
| Anmerkungen: |
Date Completed 15.06.2022 Date Revised 24.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijcard.2022.04.065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340161337 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340161337 | ||
| 003 | DE-627 | ||
| 005 | 20231226004521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2022.04.065 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340161337 | ||
| 035 | |a (NLM)35487320 | ||
| 035 | |a (PII)S0167-5273(22)00584-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van den Bosch, Eva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associations between blood biomarkers, cardiac function and adverse outcome in a young tetralogy of Fallot cohort |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2022 | ||
| 500 | |a Date Revised 24.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: To determine the potential prognostic value and clinical correlations of blood biomarkers in a cohort of patients with Tetralogy of Fallot (TOF) | ||
| 520 | |a METHODS: In the setting of multicenter prospective research studies TOF patients underwent blood sampling, cardiopulmonary exercise testing and low-dose dobutamine stress cardiac magnetic resonance (CMR) imaging. In the blood sample NT-proBNP, GDF-15, Galectin-3, ST-2, DLK-1, FABP4, IGFBP-1, IGFBP-7, MMP-2, and vWF were assessed. During subsequent follow-up, patients were evaluated for reaching the study endpoint (cardiac death, arrhythmia-related hospitalization or cardioversion/ablation, VO2 max ≤65% of predicted). Regression analysis was used to explore the correlation between blood biomarkers (corrected for age and gender) and other clinical parameters. The potential predictive value of blood biomarkers and events were assessed with Kaplan-Meier analysis and Cox proportional hazard analysis | ||
| 520 | |a RESULTS: We included 137 Fallot patients, median age 19.2 (interquartile range: 14.6-25.7) years, median age at TOF-repair 0.9 (0.5-1.9) years. After a median follow-up of 8.7 (6.3-10.7) years, 20 (14.6%) patients reached the composite endpoint. In a multivariable cox-regression analysis corrected for age at study baseline, elevated IGFBP-7 and MMP-2 levels were associated with the composite endpoint. We also noted a correlation between DLK-1 and relative change in right ventricular end systolic volume during dobutamine stress CMR (β = -0.27, p = 0.010), a correlation between FABP4 and Max VO2 (β = -0.41, p ≤0.001 and between MMP-2 and tricuspid valve E/A ratio (β = -0.15, p = 0.037) | ||
| 520 | |a CONCLUSIONS: IGFBP-7, MMP-2 and DLK-1 levels are related to cardiac function and long-term outcome in TOF patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DLK-1 | |
| 650 | 4 | |a IGFPB-7 | |
| 650 | 4 | |a MMP-2 | |
| 650 | 4 | |a NT-proBNP | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Tetralogy of Fallot | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Dobutamine |2 NLM | |
| 650 | 7 | |a 3S12J47372 |2 NLM | |
| 650 | 7 | |a Matrix Metalloproteinase 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.24.24 |2 NLM | |
| 700 | 1 | |a van Genuchten, Wouter J |e verfasserin |4 aut | |
| 700 | 1 | |a Luijnenburg, Saskia E |e verfasserin |4 aut | |
| 700 | 1 | |a Duppen, Nienke |e verfasserin |4 aut | |
| 700 | 1 | |a Kamphuis, Vivian P |e verfasserin |4 aut | |
| 700 | 1 | |a Roos-Hesselink, Jolien W |e verfasserin |4 aut | |
| 700 | 1 | |a Bartelds, Beatrijs |e verfasserin |4 aut | |
| 700 | 1 | |a Roest, Arno A W |e verfasserin |4 aut | |
| 700 | 1 | |a Breur, Johannes M P J |e verfasserin |4 aut | |
| 700 | 1 | |a Blom, Nico A |e verfasserin |4 aut | |
| 700 | 1 | |a Boersma, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Koopman, Laurens P |e verfasserin |4 aut | |
| 700 | 1 | |a Helbing, Willem A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cardiology |d 1984 |g 361(2022) vom: 15. Aug., Seite 31-37 |w (DE-627)NLM012621196 |x 1874-1754 |7 nnns |
| 773 | 1 | 8 | |g volume:361 |g year:2022 |g day:15 |g month:08 |g pages:31-37 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijcard.2022.04.065 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 361 |j 2022 |b 15 |c 08 |h 31-37 | ||